Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Covington
Express Scripts
AstraZeneca
McKinsey
Harvard Business School
Dow
McKesson
Healthtrust

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ULTRALENTE

« Back to Dashboard

Clinical Trials for Ultralente

Trial ID Title Status Sponsor Phase Summary
NCT00222521 Insulin Glargine Vs Standard Insulin Therapy Completed Moran, Antoinette, M.D. Phase 3 This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 Insulin Glargine Vs Standard Insulin Therapy Completed Sanofi Phase 3 This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
NCT00222521 Insulin Glargine Vs Standard Insulin Therapy Completed University of Minnesota - Clinical and Translational Science Institute Phase 3 This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ultralente

Condition Name

Condition Name for Ultralente
Intervention Trials
Type 1 Diabetes 2
Impaired Glucose Tolerance 1
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ultralente
Intervention Trials
Diabetes Mellitus 4
Diabetes Mellitus, Type 2 2
Diabetes Mellitus, Type 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ultralente

Trials by Country

Trials by Country for Ultralente
Location Trials
United States 42
Canada 14
India 7
Italy 7
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ultralente
Location Trials
Texas 3
Kentucky 3
California 3
Nebraska 3
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ultralente

Clinical Trial Phase

Clinical Trial Phase for Ultralente
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ultralente
Clinical Trial Phase Trials
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ultralente

Sponsor Name

Sponsor Name for Ultralente
Sponsor Trials
Pfizer 2
Sanofi 2
Novartis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ultralente
Sponsor Trials
Industry 5
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Accenture
Chinese Patent Office
Express Scripts
Teva
AstraZeneca
Dow
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.